Philip Morris International Inc. (NYSE:PM) may look for acquisitions. Andre Calantzopoulos, Chief Executive Officer said, “The ambition is we have the clinical preclinical regulatory approval capability, and then we can outsource or partner for anything else. So we're not going to build the machine. And as we learn, we may also have to make some acquisitions in all this broad area so that we can get scale”.